BBIO · NASDAQ · STOCK
BridgeBio Pharma (BBIO) Stock Analysis
$65.34
52W $52.75 – $93.42
48/100
$12.80B
-18.3
0.97
Is BBIO Bullish or Bearish?
Mixed.
Innellis AI committee rates BridgeBio Pharma, Inc. (BBIO) Watch with a composite score of 48/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +11.80 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -8.20 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 8.27) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 202.4% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 150.7x prices in significant intangible value — Value
- ROE of only -206.7% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 8.27 adds balance-sheet risk to the value case — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- High leverage (debt-to-equity 8.27) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
48/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 97%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 150.7x prices in significant intangible value
Growth Analyst
neutral
47
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Revenue growing 202.4% YoY -- genuine top-line momentum
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 8.27) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 48.2 to 48.2.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
36.7
Neutral
MACD Histogram
0.319
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$62.84
Resistance
$83.29
Bollinger %B
0.26
Inside Bands
Price vs Moving Averages
EMA 9
$66.21
Below
EMA 21
$68.09
Below
EMA 50
$71.77
Below
EMA 200
$70.60
Below
Fundamental Analysis
Valuation
100
Growth
25
Profitability
50
Financial Health
68
Cash Flow
15
Valuation
P/E Ratio
-18.3×
P/B Ratio
-5.09×
PEG Ratio
-1.42
Dividend Yield
0.00%
52W High
$93.42
52W Low
$52.75
Quality & Growth
ROE
3512.1%
ROA
-7791.5%
Gross Margin
9334.5%
Operating Margin
-7621.6%
Revenue Growth YoY
—
Debt / Equity
-0.99
AI Fundamental Assessment
P/E ratio of -18.3 (inexpensive relative to a 15-40x range); Price-to-book of -5.1x; PEG ratio of -1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 35.1%; Return on assets of -77.9%; Net margin of -97.6%; Gross margin of 93.3%; Current ratio of 1.23 (tight short-term liquidity); Debt-to-equity of -0.99; Free cash flow per share is negative (-2.25); Most recent quarter missed estimates by 31.1%; 4 consecutive earnings misses; EPS growth decelerating (+16.0% -> +7.1% QoQ); Analyst estimates rising over recent quarters
Get the Full BBIO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →